Man Claims He Went Blind After Taking Ozempic, Shares Warning for Other Users

**Lead**

A Texas man is speaking out after claiming he went blind in his left eye while taking the popular diabetes and weight-loss drug Ozempic, issuing a stark warning to millions of Americans using the medication. The man, who asked to remain anonymous for privacy reasons, told local news outlets that he began experiencing vision problems weeks after increasing his dose of semaglutide, the active ingredient in Ozempic and Wegovy. His case adds to a growing body of reports linking the blockbuster drug to rare but serious eye conditions, including a condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden, irreversible vision loss.

**Context**

The man, a resident of Houston, said he had been taking Ozempic for approximately four months to manage his type 2 diabetes and aid in weight loss. He described the initial weeks as uneventful, with typical side effects like mild nausea and fatigue. However, after his doctor increased his dosage from 0.5 mg to 1.0 mg, he woke up one morning with a dark shadow covering the center of his vision in his left eye. Within days, the shadow expanded, and he was diagnosed with NAION by a retinal specialist. The condition, which occurs when blood flow to the optic nerve is blocked, has no known cure and can lead to permanent vision loss.

This is not an isolated incident. Over the past year, several peer-reviewed studies and case reports have documented a potential association between semaglutide and NAION. A study published in the journal *JAMA Ophthalmology* in mid-2025 found that patients taking semaglutide for weight loss or diabetes had a significantly higher risk of developing NAION compared to those on other medications. While the absolute risk remains low, the study’s authors emphasized the need for physicians to discuss these risks with patients, especially those with pre-existing conditions like hypertension or sleep apnea, which are also risk factors for NAION.

The U.S. Food and Drug Administration (FDA) has received thousands of adverse event reports related to Ozempic and similar GLP-1 receptor agonists, though the agency has not yet issued a formal warning specifically about vision loss. Novo Nordisk, the manufacturer of Ozempic and Wegovy, has stated that the safety of its products is a top priority and that it continuously monitors all adverse events. The company has pointed to clinical trials that did not show a significant increase in eye disorders, but acknowledges that rare events may only surface after widespread use.

**Analise**

The Houston man’s story highlights a critical gap in how new-generation weight-loss drugs are being prescribed and monitored. Ozempic has become a cultural phenomenon, with millions of Americans using it off-label for weight loss, often through telehealth services that may not include comprehensive eye exams. The drug’s popularity has outpaced long-term safety data, and cases like this one underscore the importance of informed consent. Patients are often aware of common gastrointestinal side effects, but rare, life-altering risks like vision loss are rarely discussed in the initial consultation.

Moreover, this case raises questions about the regulatory framework for drugs that are approved for one condition but widely used for another. While the FDA has approved Ozempic for diabetes and Wegovy for obesity, the off-label use of Ozempic for weight loss in non-diabetic patients has exploded. This has led to supply shortages and, more concerningly, a lack of standardized monitoring protocols. Eye specialists are now calling for baseline eye exams for all patients starting GLP-1 therapy, particularly those with diabetes, who are already at higher risk for eye disease.

The broader impact of this case extends beyond individual health. As the demand for these drugs continues to rise, so does the potential for rare adverse events to become more visible. The man’s decision to share his story publicly is part of a larger trend of patients using social media to document side effects, which has forced both regulators and manufacturers to respond more quickly. While the scientific community remains divided on whether semaglutide directly causes NAION or simply accelerates it in predisposed individuals, the precautionary principle suggests that patients should be fully informed before starting treatment.

For now, the Houston man is adjusting to life with limited vision in his left eye. He has stopped taking Ozempic and is exploring rehabilitation options. His message to other users is simple: “Do your research, ask your doctor about your eyes, and don’t ignore any sudden changes in your vision.” His story serves as a sobering reminder that even the most celebrated drugs carry risks, and that vigilance is essential when it comes to long-term health.

**Fontes**

- *JAMA Ophthalmology* study on semaglutide and NAION (2025) - U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) - Novo Nordisk official safety communications - Local Houston news coverage of the patient’s account